CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.…
What Makes CalciMedica Inc. (CALC) a New Buy Stock
CalciMedica (NASDAQ: CALC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.260 USD on 20 November 2026, down 91.7% over 52 weeks. Its 52-week range is 1.000 USD to 36.00 USD: the price is 96.5% below the high and 26.0% above the low.
Its market capitalisation is 8.69M USD.
CalciMedica reports return on equity of 445.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 6.87M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.